-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 21, CDE's official website showed that AstraZeneca's application for the listing of new indications for the Olapali tablet was to be included in the priority review, a single drug used to treat adult patients with BRCA1/2 mutations (embryo and/or somatic cell line) who developed disease progression after previous new hormone therapy.
Olapali is the FDA-approved first oral polyaline disphosphate keruclease (PARP) inhibitor that kills tumor cells by inhibiting PARP enzyme activity and preventing PARP from dissociating from DNA, in collaboration with DNA damage repair functional defects.
first approved for listing in the European Union and the United States in 2014.
$1,198 million and $444 million, respectively, in 2019, according to the NewPharma database of the Rubik's Cube.
Olapali was first approved for listing by the NMPA in August 2018 and has been approved for treatment in China so far: (1) Maintenance therapy in adult patients with platinum-sensitive relapsed epitheliotic ovarian cancer, fallopian tube cancer or primary peritiotic cancer after platinum-containing chemotherapy has reached full or partial remission.
maintenance treatment for advanced ovarian cancer with BRCA mutation (2).
(3) maintenance therapy for advanced epitheliotic ovarian, fallopian or primary peritary cancer with BRCA mutations.
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here
